The launch of Wegovy by Novo Nordisk in the United States as the first-ever oral GLP-1 medication for treating obesity, as well as the advancement of orforglipron by Eli Lilly, will affect competition, as companies strive to develop more convenient and better-tolerated medications that can provide good payer value
These include, but are not limited to, reassignments of HCPCS codes to APCs to rectify 2 times violations as required by the law, to address the costs of new services, to address differences in hospitals' costs that may result from changes in medical practice, and to respond to public comments
Schedule your appointment now and let the experts guide you on the right treatment plan
Lipid synthesis and storage in the fat cells reduces plasma levels of free fatty acids (FFAs) and glycerol
It can be used twice a day
This process, known as lipolysis, effectively destroys fat cells when injected into areas of unwanted fat